Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome

Cancer Cell

Volumn 24, Issue 1, 2013, Pages 90-104

  Rhyasen, Garrett W ^a,b   Bolanos, Lyndsey ^a,b   Fang, Jing ^a   Jerez, Andres ^c   Wunderlich, Mark ^a   Rigolino, Carmela ^d   Mathews, Lesley ^e   Ferrer, Marc ^e   Southall, Noel ^e   Guha, Rajarshi ^e   Keller, Jonathan ^e   Thomas, Craig ^e   Beverly, LeviJ ^f   Cortelezzi, Agostino ^g   Oliva, Esther N ^d   Cuzzola, Maria ^d   Maciejewski, Jaroslaw P ^c   Mulloy, James C ^a   Starczynowski, Daniel T ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f University of Louisville School of Medicine   (United States)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1 INHIBITOR; NAVITOCLAX; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; STEM CELL EXPANSION;

EID: 84880002232     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.05.006     Document Type: Article

References (45)

1. Bar M., Stirewalt D., Pogosova-Agadjanyan E., Wagner V., Gooley T., Abbasi N., Bhatia R., Deeg H.J., Radich J. Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression. Transl. Oncogenomics 2008, 3:137-149.
2. Barreyro L., Will B., Bartholdy B., Zhou L., Todorova T.I., Stanley R.F., Ben-Neriah S., Montagna C., Parekh S., Pellagatti A., et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012, 120:1290-1298.
3. Boldin M.P., Taganov K.D., Rao D.S., Yang L., Zhao J.L., Kalwani M., Garcia-Flores Y., Luong M., Devrekanli A., Xu J., et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J.Exp. Med. 2011, 208:1189-1201.
4. Breccia M., Alimena G. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin. Ther. Targets 2010, 14:1157-1176.
5. Camós M., Esteve J., Jares P., Colomer D., Rozman M., Villamor N., Costa D., Carrió A., Nomdedéu J., Montserrat E., Campo E. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 2006, 66:6947-6954.
6. Chen G., Zeng W., Miyazato A., Billings E., Maciejewski J.P., Kajigaya S., Sloand E.M., Young N.S. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004, 104:4210-4218.
7. Chen J., Bardes E.E., Aronow B.J., Jegga A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009, 37(Web Server issue):W305-W311.
8. Conze D.B., Wu C.J., Thomas J.A., Landstrom A., Ashwell J.D. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation. Mol. Cell. Biol. 2008, 28:3538-3547.
9. Corey S.J., Minden M.D., Barber D.L., Kantarjian H., Wang J.C., Schimmer A.D. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat. Rev. Cancer 2007, 7:118-129.
10. Durand-Reville, T., Jewell, C., Hammond, C., and Chin, D. March 2008. IRAK modulators for treating an inflammatory condition, cell proliferation disorder, immune disorder. U.S. patent WO/2008/030579.
11. Ebert B.L. Preface. The biology and treatment of myelodysplastic syndrome. Hematol. Oncol. Clin. North Am. 2010, 24:xiii-xvi.
12. Fang J., Rhyasen G., Bolanos L., Rasch C., Varney M., Wunderlich M., Goyama S., Jansen G., Cloos J., Rigolino C., et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood 2012, 120:858-867.
13. Flannery S., Bowie A.G. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem. Pharmacol. 2011, 80:1981-1991.
14. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S., Maciejewski J.P. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
15. Greenberg P.L. Current therapeutic approaches for patients with myelodysplastic syndromes. Br. J. Haematol. 2010, 150:131-143.
16. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
17. Hofmann W.K., de Vos S., Komor M., Hoelzer D., Wachsman W., Koeffler H.P. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002, 100:3553-3560.
18. Kollewe C., Mackensen A.C., Neumann D., Knop J., Cao P., Li S., Wesche H., Martin M.U. Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J.Biol. Chem. 2004, 279:5227-5236.
19. Kristinsson S.Y., Björkholm M., Hultcrantz M., Derolf A.R., Landgren O., Goldin L.R. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J.Clin. Oncol. 2011, 29:2897-2903.
20. Martin M.G., Welch J.S., Uy G.L., Fehniger T.A., Kulkarni S., Duncavage E.J., Walter M.J. Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. Leukemia 2011, 24:1662-1664.
21. Matsuoka A., Tochigi A., Kishimoto M., Nakahara T., Kondo T., Tsujioka T., Tasaka T., Tohyama Y., Tohyama K. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia 2010, 24:748-755.
22. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., Kohlhammer H., Xu W., Yang Y., Zhao H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2010, 470:115-119.
23. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
24. O'Dwyer M.E., Mauro M.J., Druker B.J. STI571 as a targeted therapy for CML. Cancer Invest. 2003, 21:429-438.
25. Park, C., Pang, W., Price, E., Pluvinage, J., Schrier, S., and Weissman, I. (2011). Hematopoietic stem cells are the disease-initiating cells in the myelodysplastic syndromes. Paper presented at ASH Annual Meeting, San Diego, CA.
26. Pellagatti A., Cazzola M., Giagounidis A., Perry J., Malcovati L., Della Porta M.G., Jädersten M., Killick S., Verma A., Norbury C.J., et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010, 24:756-764.
27. Powers J.P., Li S., Jaen J.C., Liu J., Walker N.P., Wang Z., Wesche H. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg. Med. Chem. Lett. 2006, 16:2842-2845.
28. Sekeres M.A. Are we nearer to curing patients with MDS?. Best Pract. Res. Clin. Haematol. 2010, 23:481-487.
29. Sekeres M.A. The epidemiology of myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 2010, 24:287-294.
30. Sokol L., Caceres G., Volinia S., Alder H., Nuovo G.J., Liu C.G., McGraw K., Clark J.A., Sigua C.A., Chen D.T., et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br. J. Haematol. 2011, 153:24-32.
31. Starczynowski D.T., Karsan A. Innate immune signaling in the myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 2010, 24:343-359.
32. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., Sung S., Morin R., Muranyi A., Hirst M., Hogge D., Marra M., Wells R.A., et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 2010, 16:49-58.
33. Starczynowski D.T., Kuchenbauer F., Wegrzyn J., Rouhi A., Petriv O., Hansen C.L., Humphries R.K., Karsan A. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp. Hematol. 2011, 39:167-178. e4.
34. Starczynowski D.T., Morin R., McPherson A., Lam J., Chari R., Wegrzyn J., Kuchenbauer F., Hirst M., Tohyama K., Humphries R.K., et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011, 117:595-607.
35. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
36. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 2006, 103:12481-12486.
37. Tehranchi R., Woll P.S., Anderson K., Buza-Vidas N., Mizukami T., Mead A.J., Astrand-Grundström I., Strömbeck B., Horvat A., Ferry H., et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N.Engl. J. Med. 2010, 363:1025-1037.
38. Thomadaki H., Scorilas A. Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect. Tissue Res. 2008, 49:261-264.
39. Tohyama K., Tohyama Y., Nakayama T., Ueda T., Nakamura T., Yoshida Y. A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages. Br. J. Haematol. 1995, 91:795-799.
40. Vanderwerf S.M., Svahn J., Olson S., Rathbun R.K., Harrington C., Yates J., Keeble W., Anderson D.C., Anur P., Pereira N.F., et al. TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. Blood 2009, 114:5290-5298.
41. Vasikova A., Belickova M., Budinska E., Cermak J. A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome. Leuk. Res. 2010, 34:1566-1572.
42. Wang Z., Wesche H., Stevens T., Walker N., Yeh W.C. IRAK-4 inhibitors for inflammation. Curr. Top. Med. Chem. 2009, 9:724-737.
43. Wunderlich M., Chou F.S., Link K.A., Mizukawa B., Perry R.L., Carroll M., Mulloy J.C. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 2010, 24:1785-1788.
44. Yang Y.F., Chen Z., Hu S.L., Hu J., Li B., Li J.T., Wei L.J., Qian Z.M., Lin J.K., Feng H., Zhu G. Interleukin-1 receptor associated kinases-1/4 inhibition protects against acute hypoxia/ischemia-induced neuronal injury invivo and invitro. Neuroscience 2011, 196:25-34.
45. Zhao J.L., Rao D.S., Boldin M.P., Taganov K.D., O'Connell R.M., Baltimore D. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc. Natl. Acad. Sci. USA 2011, 108:9184-9189.